A Phase 1/2 interventional study of Anakinra in Poor Graft Function, Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ruijin Hospital · Phase 1/2, Interventional, and Prevention
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and that the interleukin-1 receptor antagonist (IL-1Ra, Anakinra) can reverse this process. Sustained low-level IL-1 signaling also drives hematopoietic stem cell (HSC) dysfunction, including progression of clonal hematopoiesis and transformation to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). A prior phase 2 trial of IL-1 inhibition in lower-risk MDS demonstrated hematologic improvement without an increased risk of leukemic transformation. Based on these findings, this study hypothesizes that early administration of Anakinra after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with MDS, by inhibiting IL-1β signaling, improving the bone marrow microenvironment, and reducing the occurrence of poor graft function (PGF), does not increase the risk of post-transplant relapse. The study comprises two parts: a dose-escalation phase to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of Anakinra in post-allo-HSCT patients, and an efficacy-validation phase to evaluate the preventive effect of Anakinra at the RP2D on PGF.
Background and Rationale. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative approach for MDS; however, a subset of patients develops poor graft function (PGF)-defined as persistent cytopenias in two or more lineages despite achievement of full donor chimerism (≥95%)-following otherwise successful engraftment. PGF is associated with significant morbidity, recurrent infections, transfusion dependence, and increased non-relapse mortality, and no standard therapy exists.
Preclinical and translational evidence implicates the interleukin-1 (IL-1) inflammatory pathway in the bone marrow failure of MDS. Sustained low-level IL-1 signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), a critical cytokine for hematopoietic stem cell (HSC) survival and self-renewal, thereby causing failure of the marrow microenvironment's hematopoietic supportive capacity. Pharmacologic blockade of IL-1 signaling with the interleukin-1 receptor antagonist (IL-1Ra, Anakinra) can reverse this process and restore stromal supportive function in experimental models. Beyond the post-transplant setting, chronic IL-1 signaling also drives HSC dysfunction, including progression of clonal hematopoiesis and transformation to MDS or acute myeloid leukemia (AML). Importantly, a prior phase 2 trial of IL-1 inhibition in lower-risk MDS demonstrated hematologic improvement without an increased risk of leukemic transformation, supporting the safety of IL-1 blockade with respect to disease acceleration.
Study Hypothesis. Based on these findings, this study hypothesizes that early administration of Anakinra after allo-HSCT in patients with MDS-by inhibiting IL-1 signaling, improving the bone marrow microenvironment, and reducing the occurrence of PGF-does not increase the risk of post-transplant relapse.
Study Design. This is a prospective, multicenter, open-label, single-arm phase 1/2 study comprising two parts. Part 1 (dose-escalation) uses a standard 3+3 design to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of subcutaneous Anakinra administered thrice weekly from day 0 through day +28 after allo-HSCT; dose levels are 100 mg, 200 mg, and 300 mg, with dose-limiting toxicities assessed during the treatment and observation period. Unlike conventional cytotoxic agents for which the recommended dose equals the MTD, Anakinra is a biologic agent for which the optimal biological dose may be lower than the MTD; the RP2D will therefore be selected by integrating safety, IL-1 pathway inhibition, and preliminary biological activity. Part 2 (efficacy-validation) administers Anakinra at the RP2D subcutaneously thrice weekly from day 0 through day +28 after allo-HSCT; the primary efficacy endpoint is the cumulative incidence of PGF by day +100, assessed against historical controls. Secondary endpoints include overall survival, non-relapse mortality, cumulative incidence of relapse, acute and chronic graft-versus-host disease and post-transplant relapse risk.
2,165 studies on the registry are indexed under Myelodysplastic Syndromes; 322 are open to participants now.
This study's planned enrollment of 66 is above the median of 39 across 1,771 interventional studies indexed under Myelodysplastic Syndromes.
Browse Myelodysplastic Syndromes studies →Ruijin Hospital is the lead sponsor of 667 studies on the registry; 376 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Part 1. Anakinra SC thrice weekly Day 0→+28; dose levels 100/200/300 mg assigned via standard 3+3 escalation to determine MTD and RP2D; Part 2. Anakinra at the RP2D (from Part 1) SC thrice weekly Day 0→+28, to evaluate prevention of poor graft function.
Biological: Anakinra
Recombinant interleukin-1 receptor antagonist. Subcutaneous, thrice weekly from Day 0 through Day +28 after allo-HSCT.
incidence of poor graft function (PGF) by Day +100
Persistent ≥2 lineage cytopenias, donor chimerism ≥95%
Time frame: 100 days post-HCT
Overall survival
Overall survival (OS) at 2 year
Time frame: 2 year post-HCT
Non-relapse mortality
Cumulative incidence of non-relapse mortality at 1 year
Time frame: 2 year post-HCT
Relapse
Cumulative incidence of relapse at 1 year
Time frame: 2 year post-HCT
Incidence of acute GVHD
Incidence of acute GVHD within 180 days post-HCT
Time frame: 180 days post-HCT
Plan to share: Yes — De-identified individual participant data will be shared upon reasonable request to the principal investigator after publication of the main results.
Time frame: After publication of the main results.
Access criteria: Upon reasonable request to the principal investigator.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2027, 13 months later.
Of 72 non-industry phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's planned 13 months is below that.
Counting every sponsor, half of 111 studies reached it within 73 months; a quarter within 49 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein